Keros Therapeutics (KROS) Change in Cash (2019 - 2025)
Keros Therapeutics filings provide 7 years of Change in Cash readings, the most recent being -$406.1 million for Q4 2025.
- On a quarterly basis, Change in Cash fell 1488.37% to -$406.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$272.5 million, a 218.99% decrease, with the full-year FY2025 number at -$272.5 million, down 218.99% from a year prior.
- Change in Cash hit -$406.1 million in Q4 2025 for Keros Therapeutics, down from $3.3 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $160.6 million in Q1 2025 to a low of -$406.1 million in Q4 2025.
- Median Change in Cash over the past 5 years was $900500.0 (2022), compared with a mean of $1.1 million.
- Biggest five-year swings in Change in Cash: soared 5071.22% in 2023 and later plummeted 1488.37% in 2025.
- Keros Therapeutics' Change in Cash stood at $8.7 million in 2021, then skyrocketed by 355.84% to $39.6 million in 2022, then rose by 9.17% to $43.3 million in 2023, then plummeted by 32.38% to $29.2 million in 2024, then plummeted by 1488.37% to -$406.1 million in 2025.
- The last three reported values for Change in Cash were -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025) per Business Quant data.